Enfin disponible en France, grâce à une étonnante formule France, 100% naturelle, vous pouvez maintenant dire stop à vos problèmes d’impuissance et à vos troubles de la virilité. Cette formule révolutionnaire agit comme un véritable achat levitra
naturel. Ses résultats sont immédiats, sans aucun effet secondaire et vos érections sont durables, quelque soit votre âge. Même si vous avez plus de 50 ans !
Microsoft word - duloxeprin.doc
Medizen Pharmaceutical Industries.
Delayed-release capsules containing enteric coated pellets.
Enteric coated pellets of duloxetine hydrochloride 33.7mg equivalent to duloxetine 30mg.
Lactose, gelatin, hypromellose, hydroxypropyl methyl cellulose acetate succinate, sodium lauryl
sulfate, sucrose, talc, titanium dioxide and triethyl citrate.
Duloxetine is a potent inhibitor of neuronal serotonin and norepinephrine reuptake and a less potent
inhibitor of dopamine reuptake. Duloxetine does not inhibit monoamine oxidase (MAO.)
Although the exact mechanism of the antidepressant, central pain inhibitory and anxiolytic actions of
duloxetine in humans are unknown, these actions are believed to be related to its potentiation of
serotonergic and noradrenergic activity in the CNS.
Orally administered, duloxetine hydrochloride is well absorbed. The maximum plasma
concentrations (Cmax) of duloxetine occurs 6 hours post-dose. Food does not affect the Cmax of
duloxetine. Duloxetine is highly bound (>90%) to proteins in human plasma. Plasma protein binding of
duloxetine is not affected by renal or hepatic impairment.
Duloxetine has an elimination half-life of about 12 hours. Steady state plasma
concentrations are achieved after 3 days of dosing. Elimination of duloxetine is mainly through hepatic
Metabolism and Elimination:
Duloxetine undergoes extensive metabolism to numerous metabolites.
Only trace amounts (<1% of the dose) of unchanged duloxetine are present in the urine. Most of the
duloxetine dose (about 70%) appears in the urine as metabolites. About 20% is excreted in the feces.
1- Treatment of Major Depressive Disorder (MDD.)
2- Management of neuropathic pain associated with diabetic peripheral neuropathy.
3-Treatment of generalized anxiety disorder.
Dosage & Administration:
Duloxeprin should be swallowed whole and should not be chewed or crushed nor should the capsule
be opened and its contents sprinkled on food or mixed with liquids. Duloxeprin is given irrelevant to
Major Depressive Disorder:
Duloxeprin should be administered at a total dose of 40mg/day to
60mg/day (given either once a day or as 30mg BID) irrelevant to meals.
Diabetic Peripheral Neuropathic Pain:
Duloxeprin should be administered at a total dose of
60mg/day given once a day irrelevant to meals.
Generalized Anxiety Disorder:
The recommended starting dose for Duloxeprin is 60mg administered
once daily irrelevant to meals. For some patients, it may be desirable to start at 30mg once daily for 1
week to allow patients to adjust to the medication before increasing the dose to 60mg once daily.
Stress Urinary Incontinence
: 60mg once daily.
- Hypersensitivity to duloxetine or any of the inactive ingredients present in the drug.
- Duloxetine use was associated with an increased risk of mydriasis; therefore, its use should be
avoided in patients with uncontrolled narrow-angle glaucoma. Concomitant use in patients taking
Monoamine Oxidase Inhibitors (MAOIs) is contraindicated.
Nausea, dry mouth, constipation, somnolence, hyperhidrosis, decreased appetite & weight, fatigue,
dizziness, tremors, hot flushes, blurred vision, insomnia, anxiety, decreased libido, erectile &
ejaculatory dysfunctions, palpitations, atrial fibrillation, coronary artery disease, myocardial infarction,
Inhibitors of CYP1A2 & CYP2D6:
Concomitant use of Duloxeprin with these potent inhibitors may
result in higher concentrations of the drug in the plasma. Drugs Metabolized by CYP2D6:
is a moderate inhibitor of CYP2D6. When Duloxetine was administered in conjunction with
desipramine (a CYP2D6 substrate) the AUC of desipramine increased 3-folds.Therefore, co-
administration of Duloxeprin with other drugs that are extensively metabolized by this isozyme, and
which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants,
such as nortriptyline, amitriptyline and imipramine) & phenothiazines should be approached with
caution. Serotonergic Drugs:
Caution is advised when Duloxeprin is co administered with other drugs
that may affect the serotonergic neurotransmitter systems such as triptans and linezolid.
Pregnancy and Lactation:
There are no adequate and well-controlled studies in pregnant women. Therefore, Duloxeprin should be
used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Because the
safety of duloxetine in infants is not known, nursing while on Duloxeprin is not recommended.
Precautions and Warnings:
There is an increased risk of suicidal thoughts and behavior in children, adolescents and young adults
taking antidepressants for Major Depressive Disorder (MDD) and other psychiatric disorders.
Duloxeprin is not approved for use in pediatric patients.
Duloxeprin increases the risk of elevation of serum transaminase levels and bilirubin. So; it should not
be prescribed to patients with substantial alcohol use or evidence of chronic liver diseases.
Orthostatic hypotension and syncope have been reported with therapeutic doses of Duloxeprin. The
risk of blood pressure decrease may be greater in patients taking concomitant medications that induce
orthostatic hypotension (such as antihypertensives.) Blood pressure should be measured prior to
initiating treatment and periodically measured throughout treatment.
Duloxeprin should be used cautiously in patients with a history of mania or seizures.
Discontinuation of Treatment with Duloxeprin:
The following symptoms may occur upon
discontinuation of treatment with Duloxeprin: Dizziness, nausea, headache, paresthesia, vomiting,
irritability, nightmares, insomnia, diarrhea, anxiety, hyperhidrosis and vertigo. A gradual reduction in
the dose, rather than abrupt cessation, is recommended to minimize the risk of these symptoms.
Carton box containing 1 or 2 pvdc/aluminum strips; each strip has 14 capsules.
Keep at a temperature not exceeding 30°C in a dry place.
Instructions for Patients:
-Keep this leaflet. You may need to read it again.
-If you have any further questions, please refer to your doctor or pharmacist.
-Duloxeprin should be swallowed whole and should not be chewed or crushed nor should the contents
be sprinkled on food or mixed with liquids.
Produced by Medizen Pharmaceuticals Industries
Versatile 1 PPO, RX1, Hearing Benefits-at-a-Glance Western Michigan Health Insurance Pool Group Number: 71565 Package Code(s):001 Section Code(s):1000, 1100 In-Network Out-of-Network Deductible, Copays/Coinsurance and Dollar Maximums Deductible - per calendar year Copays/Coinsurance 30% Note : Services without a network are covered at the in-network level. O
Quick Guide to Pharmacotherapy in Tobacco Treatment NICOTINE REPLACEMENT (NRT) Combining long-acting NRT (patch) with a short-acting NRT (gum, lozenge, or inhaler) is more effective than using a single type of NRT LONG-ACTING PRODUCTS PATCH 7 mg, 14 mg, 21 mg Dose: 1 patch every 24 hrs. SHORT-ACTING PRODUCTS GUM LOZENGE or MINI-LOZENGE NASAL SPRAY (Nicotrol® NS) INHALER (N